## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bruck, et al.

Serial No.: 09/936,456 I.A. Filing Date: 09 March 2000

For: Novel Compounds

Group Art Unit No.: Unknown

Examiner: Unknown

## **BOX PCT**

Commissioner for Patents Washington, DC 2023 l

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: **BOX PCT**, Commissioner for Patents, Washington, D.C. 20231, on December 19, 2001.

Colleen Hanagan

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.56

Applicants herein make available to the Patent and Trademark Office copies of the documents:

- ☐ listed on enclosed Form PTO/SB/08A/B (Formerly PTO-1449), in accordance with 37 CFR 1.98(a)(2); and
- listed on enclosed copies of Forms PTO-1449, PTO-892 or PTO/SB/08A/B, which forms recited the application information for applications to which this application claims priority under 35 U.S.C. §120, but have been edited to indicate the current application data. Pursuant to 37 CFR 1.98(d), NO COPIES OF THESE DOCUMENTS ARE ENCLOSED. The prior applications that provide the source of these documents are:

Serial No. \_\_\_\_\_;

Serial No.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of this application. It is believed that the Examiner will concur with Applicant's belief that the foregoing references do not adversely affect the patentability of the subject matter presently claimed, taken alone or in combination.

It is requested that the listed references be included in the "References Cited" portion of any patent issuing from this application.



Under 37 CFR 1.97(i), Applicants understand that non-complying Information Disclosure Statements will be placed in the file but not considered by the Office, however, under Reply to Comment 8 of the Federal Register, page 2024, Applicants will be informed when information is not considered.

(1)	This Information Disclosure Statement is being filed:							
		within three months of the filing date of the patent application.						
		within three months of the date of entry into the national stage as so forth in 37 CFR 1.491 of the international application.						
	$\boxtimes$	before the mailing date of a first Office Action on the merits.						
		after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action under 37 CFR 1.11 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by:						
		the Statement under 37 CFR 1.97(e) (see "Statement" below);						
		or						
		the Fee of \$180.00 set forth in 37 CFR 1.17(p); or						
		No fee is owed by the applicants.						
		after the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by the Statement under 37 CFR 1.97(e), a Petition requesting consideration of the Information Disclosure Statement and the Petition Fee of \$130.00 set forth in 37 CFR 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).						
(2)	Stater	nent						
		The <b>undersigned attorney</b> hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.						
	(If this box is checked, do not check any further Statement boxes.)							
	or							
	The <b>person signing immediately below</b> hereby states that no information contained in the Information Disclosure was cite communication from a foreign patent office in a counterpart patent application or, to the knowledge of the person signing making reasonable inquiry, was known to any individual design 37 CFR 1.56(c) more than three months prior to the filing of Information Disclosure Statement.							

		The pe	person making the statement is:						
			the inventor(s) who sign(s) below:						
			Signature of the Inventor(s)						
			Typed or Printed Name of the Inventor(s)						
			or						
			a person who is substantively involved in the preparation or prosecution of the application, and who is associated with the inventor(s), or with the assignee, or with anyone to whom there is an obligation to assign the application (37 CFR 1.565(c)) and who signs below:						
			Signature of the Person(s)						
			Typed or Printed Name of the Person						
	Address of Person Signing								
			or						
			the undersigned attorney who signs on the basis of the information:						
			supplied by the inventor(s).						
			supplied by an individual designated in 37 CFR 1.56(c).						
			in the attorney's file.						
			Signature of the attorney						
(3)	Petiti	ion							
			Applicants hereby petitions the Assistant Commissioner to consider the references listed in this Information Disclosure Statement and on the enclosed Form PTO/SB/08A and 08B (Formerly PTO-1449), in the examination of the above-identified patent application. (This box checked only if a Final Office Action has issued)						
	(4)	Fees							
		$\boxtimes$	No Fee is owed by the applicants.						
			The IDS Fee of \$180.00 under 37 CFR 1.17(p) is enclosed herewith.						
			The Petition Fee of \$130.00 under 37 CFR 1.17(i)(1) is enclosed herewith.						

(5)	Meth	Method of Payment of Fees					
		Attached is a check in the amount of \$180.00.					
		Charge Account No. 50-0258 in the amount of \$ 180.00. (A duplicate of this request is attached).					
(6)	Autho	Authorization to Charge Additional Fees					
	$\boxtimes$	If any additional fees are owed in connection with this communication, please charge Deposit Account No. 50-0258					
(7)	Instru	Instructions as to Overpayment					
	$\boxtimes$	Please credit Account No. 50-0258 for any overpayment.					
		Please refund Dechert Price & Rhoads in the amount of \$					
A prompt an	d favora	ble response is earnestly solicited.					
		Degreet fully gubmitted					

Respectfully submitted,

Teresa O. Bittenbender Registration No. 47,425 Attorney for Applicants

DECHERT 1717 Arch Street 4000 Bell Atlantic Tower Philadelphia, PA 19103 Fax: (215) 994-2222 Attn.: Teresa O. Bittenbender, Esq. (215) 994-2213

124618.1.07

Form P1 (Modifie	ed) (ı	Information Disclostatement by Appuse several Sheets	rademark Off  sure  blicant  if necessary)	fice	Art No. Unkn  Examiner Unkn			56 al. 2000		
			U.S. PATE	NT DOCL	JMENTS			·		
Exmr Initial		Patent Number	Issue Date	P	Patentee		Sub- Class	Filing Date If Appropriate		
		<u> </u>					ļ			
					<u></u>					
						<b>_</b>	ļ <u></u> -			
ļ										
							ļ	<del>-</del>		
	-				<del></del> -	<del> </del>	<del>                                     </del>			
<u> </u>							101			
	_	FOREIGN PATEN		HED FORE	IGN PATENT A	APPLICAT	·	1		
Exmr Initial		Document Number	Publn Date	Cou	ntry or Patent Office	Class	Sub- Class	Translation? Yes No		
		WO 98 32865	30.07.98	WIPO						
		WO 96 08514	21.03.96	WIPO						
		WO 99 49030	30.09.99	WIPO						
-		WO 99 49055	30.09.99	WIPO						
	-									
OTHE	R DO	CUMENTS (Includi	ng Author, Ti	tle, Date,	Pertinent Page	s, Place	of Public	ation * *)		
	EMBL Sequence Database, 23 November 1998, Accession No. Al274929.  EMBL Sequence Database, 24 November 1998, Accession No. Al281211.									
		International Search Report from International Application No. PCT/EP00/02048.								
					· · · · · · · · · · · · · · · · · · ·					
								- <del></del>		
Examir	ner				Date	e Conside	red			

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO - 1449 [6-4])

- Use publication date indicated on the patent or published application. 37 CFR 1.98(b).
- \*\* The place or publication refers to the name of the journal, magazine or other publication in which the article was published. Notice of January 9, 1992, 1135 O.G. 13 to 25 at 20.